Progress Report from RVX-208 Phase 1 Clinical Study

Calgary, Canada (ots/PRNewswire) -

- Resverlogix Sees Early Success and Expedites Phase 2 Plans

TSX Exchange Symbol: RVX Resverlogix is pleased to announce
preliminary data from the RVX-208 Phase 1 safety and pharmacokinetics
study. Forty healthy volunteers have so far been treated of which
sixteen have received multiple doses. As anticipated from the
extensive Investigational New Drug toxicology studies no safety and
tolerance problems have been encountered at any of the given doses.
"The pharmacokinetics (drugability) of RVX-208 has exceeded our
highest expectations," stated Donald J. McCaffrey, President & CEO of
Resverlogix. "We are very confident about the further progress of the
RVX-208 clinical program and the eventual successful completion of
Phase 1. The current phase 1 study includes a total of 80 healthy men
and women in a study comprising three arms: single dose escalation,
food vs. fasted effect on pharmacokinetics and 3 cohorts with 7-day
multiple dosing."

McCaffrey noted, "Due to the successful early trending of our
Phase 1 program we have decided that upon official completion of the
trial, FDA discussions and approval, we will be expediting our plans
for a Phase 2 trial. This could shorten the time to reach our Phase 2
trial by several months. In addition, follow on studies in
cardiovascular disease patients are being discussed with potential
collaborators. The medical community recognizes that permanently
increasing ApoA-I production, plasma HDL and promoting reverse
cholesterol transport by a small molecule has unprecedented potential
to cure atherosclerosis."

About Cardiovascular Disease (CVD)

CVD can be generally defined as any abnormal condition
characterized by dysfunction of the heart and blood vessels. CVD
includes atherosclerosis (especially coronary heart disease which can
lead to heart attacks), cerebrovascular disease (stroke), and
hypertension (high blood pressure). The underlying cause of most CVD
is a gradual clogging of the arteries (atherosclerosis) that supply
blood to the heart, brain and other vital organs.

The American Heart Association estimates that almost 80 million
American Adults have one or more types of cardiovascular disease. CVD
remains the number one killer of developed nations. Nearly 2400
Americans die each day from cardiovascular disease - that is 1 person
will die every 36 seconds.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in
the development of novel therapies for important global medical
markets with significant unmet needs. The NexVas(TM) program is the
Company's primary focus which is to develop novel small molecules
that enhance ApoA-I. These vital therapies address the grievous
burden of atherosclerosis and other important diseases such as acute
coronary syndrome, diabetes, Alzheimer's and other vascular
disorders. The Company's secondary focus is TGF-Beta Shield(TM), a
program that aims to address burgeoning grievous diseases, such as
cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock
Exchange (TSX:RVX). For further information please visit
http://www.resverlogix.com.

This news release may contain certain forward-looking statements
that reflect the current views and/or expectations of Resverlogix
Corp. with respect to its performance, business and future events.
Such statements are subject to a number of risks, uncertainties and
assumptions. Actual results and events may vary significantly. The
TSX Exchange does not accept responsibility for the adequacy or
accuracy of this news release.

Website: http://www.resverlogix.com

ots Originaltext: Resverlogix Corp.
Im Internet recherchierbar: http://www.presseportal.de

$story.getcontactHeadline()
For further information: Theresa Kennedy, VP, Corporate
Communications, Resverlogix Corp., Phone: +1-604-538-7072, Fax:
+1-403-256-8495, Email: Theresa@resverlogix.com; Sarah Zapotichny,
Manager, Investor Relations, Resverlogix Corp., Phone:
+1-403-254-9252, Fax: +1-403-256-8495, Email: Sarah@resverlogix.com


	hier anmelden...